Volume 3
Number 2

HIV SURVEILLANCE DATA TABLES

Core Indicators for Monitoring the Ending the HIV Epidemic Initiative *(Preliminary Data)*:

National HIV Surveillance System Data Reported through March 2022; and Preexposure Prophylaxis (PrEP) Data Reported through December 2021

Centers for Disease Control and Prevention
National Center for HIV, Viral Hepatitis, STD, and TB Prevention

This issue of *HIV Surveillance Data Tables* is published by the Division of HIV Prevention (DHP), National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, Georgia.

Data are presented for diagnoses of HIV infection reported to CDC through March 2022 and preexposure prophylaxis (PrEP) data reported through December 2021.

Suggested citation

Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative (preliminary data): National HIV Surveillance System data reported through March 2022; and preexposure prophylaxis (PrEP) data reported through December 2021. *HIV Surveillance Data Tables* 2022;3(2). https://www.cdc.gov/hiv/library/reports/surveillance-data-tables/. Published August 2022. Accessed [date].

On the Web: https://www.cdc.gov/hiv/library/reports/surveillance-data-tables/

Confidential information, referrals, and educational material on HIV infection

CDC-INFO
1-800-232-4636 (in English, en Español)
1-888-232-6348 (TTY)
http://wwwn.cdc.gov/dcs/ContactUs/Form

Acknowledgments

HIV Surveillance Data Tables was prepared by the following staff and contractors of the Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC: Anna Satcher Johnson, Zanetta Gant, Ya-lin Huang, Dawn Smith, Jianmin Li, Xiaohong Hu, Sue Reynolds, Hao Chang, Pei Hou, Gordon Le, Shawn McCort, Weiming Zhu, Lei Yu, Ishwarya Ravichandran, Norma Harris, and Michael Friend (editing and desktop publishing).

The Web and Consumer Services Team of the Prevention Communications Branch are acknowledged for their contributions to the report website.

Publication of *HIV Surveillance Data Tables* was made possible by the contributions of the state and territorial health departments and the HIV surveillance programs that provided surveillance data to CDC.

Contents

The *Ending the HIV Epidemic in the U.S.* (EHE) initiative leverages critical scientific advances in HIV prevention, diagnosis, treatment, and outbreak response [1]. The goal of the initiative is to reduce new HIV infections by 75% by 2025 and then by at least 90% by 2030. The Centers for Disease Control and Prevention (CDC) routinely releases HIV Surveillance Data Tables on the core indicators for EHE to allow for more timely monitoring of progress. The full list of EHE core indicators and their definitions can be found in the Technical Notes of the *Core Indicators for Monitoring the Ending the HIV Epidemic Initiative* report at https://www.cdc.gov/hiv/pdf/library/reports/surveillance-data-tables/vol-1-no-1/cdc-hiv-surveillance-tables-vol-1-no-1.pdf.

The tables included in this report provide *preliminary* data on HIV diagnoses and linkage to HIV medical care reported to CDC as of March 2022 for the years 2021 and 2022, and data on preexposure prophylaxis (PrEP) coverage for the years 2019–2021 (preliminary). Data for the 3 indicators are provided at the national, state, and county levels (EHE Phase I jurisdictions only). See Tabulation and Presentation of Data for details on how the indicators are calculated.

Tabulation and Presentation of Data

Diagnoses of HIV Infection

Diagnoses of HIV infection are the numbers of persons aged ≥13 years with HIV diagnosed during January 2021 through March 2022 (Tables 1a–d). Data presented were reported (after the removal of personally identifiable information) to CDC.

An evaluation of surveillance data (2015–2019 diagnoses) found that, on average, approximately 75% of HIV diagnoses are reported to CDC during the year of diagnosis and approximately 95% of HIV diagnoses are reported to CDC by the end of the following year. Data reported to the National HIV Surveillance System (NHSS) are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

More information on counting diagnoses of HIV infection can be found at https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-33/ (*HIV Surveillance Report, 2020*).

Linkage to HIV Medical Care

Linkage to HIV medical care within 1 month of HIV diagnosis is measured for persons aged ≥13 years whose infection was diagnosed during 2021 and who resided in any of the jurisdictions (including EHE Phase I jurisdictions) with complete reporting of laboratory data to CDC at the time of diagnosis (Tables 2a–c). The numerator is the number of persons aged ≥13 years whose HIV infection was diagnosed during 2021 and who had ≥1 CD4 T-lymphocyte (CD4) or viral load (VL) tests within 1 month of HIV diagnosis. The denominator is the number of persons aged ≥13 years whose HIV infection was diagnosed during 2021. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting delay to account for delays in reporting of laboratory results to NHSS; therefore, data on linkage to HIV medical care in these surveillance tables are for persons whose HIV infection was diagnosed during 2021 and was reported to NHSS through March 2022. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kentucky, Pennsylvania (excluding Philadelphia), Puerto Rico, and Vermont.

Data reported to NHSS are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

More information on calculating linkage to care can be found at https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-27-no-3/ (*Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2020*).

Preexposure Prophylaxis Coverage

Preexposure prophylaxis (PrEP) coverage, reported as a percentage, is defined as the number of persons aged ≥16 years classified as having been prescribed PrEP during the specified year divided by the estimated number of persons aged ≥16 years who had indications for PrEP during the specified year (Tables 3a–c). PrEP coverage is an EHE indicator that is not a reportable disease or condition and is not reported to

NHSS. Multiple data sources, described below, are used to calculate PrEP coverage.

Please use caution when interpreting PrEP data. Different data sources were used in the numerator and denominator to calculate PrEP coverage.

Persons prescribed PrEP

National pharmacy data from the IQVIA Real World Data—Longitudinal Prescriptions database (hereafter, IQVIA database) are used to classify persons aged ≥16 years who have been prescribed PrEP in the specific year. The IQVIA database captures prescriptions from all payers and represents approximately 92% of all prescriptions from retail pharmacies and 60%–86% from mail-order outlets in the United States. The database does not include prescriptions from some closed health care systems that do not make their prescription data available to IQVIA. Therefore, these are minimum estimates of PrEP coverage. The annual number of persons classified as having been prescribed PrEP was based on a validated algorithm that discerns whether tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) was prescribed for PrEP after excluding prescriptions for HIV treatment, hepatitis B treatment, or HIV postexposure prophylaxis [2–4]. Tenofovir alafenamide and emtricitabine (TAF/FTC) was approved as an alternative drug for PrEP by the U.S. Food and Drug Administration (FDA) in October 2019. Starting in 2019, TAF/FTC was included in the algorithm to classify the number of persons prescribed PrEP.

The number of persons classified as having been prescribed PrEP is reported by sex, age group, and race/ethnicity. Transmission category data are not available in the IQVIA database, and race/ethnicity data are available for <40% of persons with PrEP prescriptions. Please use caution when interpreting PrEP data by race/ethnicity. Race/ethnicity categories available in the IQVIA database include White, Black/African American, Hispanic/Latino, and other. The number of persons prescribed PrEP for each racial/ethnic group presented in this report was extrapolated by applying the racial/ethnic distribution of known records to those for which data on race/ethnicity were unknown.

Geographic designations

In the IQVIA database, a person's location is reported as a 3-digit ZIP code prefix (hereafter, ZIP3) assigned by the U.S. Postal Service. To estimate the number of persons prescribed PrEP at the state or county level, a probability-based approach is used to crosswalk between ZIP3s and states/counties by using data from (a) the U.S. Census Bureau's American Community Survey (ACS) 5-year estimates by ZIP Code Tabulation Areas (ZCTAs) [5], and (b) the U.S Department of Housing and Urban Development's ZIP Code Crosswalk Files [6]. Because of reliability concerns, subnational estimates of <40 are not included.

Persons with PrEP indications

ACS and U.S. Census Bureau files were used to estimate the number of men who have sex with men (MSM) in a jurisdiction [7, 8]. Next, behavioral data from the National Health and Nutrition Examination Survey (NHANES) were used to estimate the proportion of HIV-negative MSM with indications for PrEP [9].

The number of HIV-negative MSM with indications for PrEP was multiplied by the ratio of percentage of diagnoses during the specified year attributed to other major transmission risk groups compared to the percentage among MSM in a given state or county. The estimated numbers of persons with indications for PrEP in the 3 major transmission risk groups (MSM, heterosexuals, persons who inject drugs) in each jurisdiction were then summed to yield a state- or county-specific estimate. State estimates were then summed for a national total of persons with indications for PrEP [7]. Jurisdictional estimates were rounded to the nearest 10.

The tables included in this report provide updated data on PrEP coverage for the years 2019–2021 by using the IQVIA data reported through December 2021. IQVIA conducts data quality assurance activities. As a result, the number of persons classified as having been prescribed PrEP in a given year might change from time to time. The impact of the changes may vary by demographic category nationally and by jurisdiction. The data sources used to estimate the number of persons with indications for PrEP have different schedules of availability. Consequently, the availability of a denominator lags the availability of a numerator by approximately 1 year. PrEP coverage data with a lagged denominator are considered preliminary.

For this release of *HIV Surveillance Data Tables*, 2018 denominators were used for 2019 and 2020 PrEP coverage data; consequently, 2019 and 2020 PrEP coverage data are considered preliminary.

In addition to being preliminary, data for the year 2020 should be interpreted with awareness of the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions [10].

More information on calculating PrEP coverage can be found at https://www.cdc.gov/hiv/library/reports/hiv-surveillance/vol-27-no-3/ (*Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2020*).

REFERENCES

1. HHS. What is *Ending the HIV Epidemic in the U.S.*? https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview. Updated June 2, 2021. Accessed July 21, 2022.
2. Wu H, Mendoza MC, Huang YA, Hayes T, Smith DK, Hoover KW. Uptake of HIV preexposure prophylaxis among commercially insured persons—United States, 2010–2014. *Clin Infect Dis* 2017;64(2):144–149. doi:10.1093/cid/ciw701
3. CDC [Huang YA, Zhu W, Smith DK, Harris N, Hoover KW]. HIV preexposure prophylaxis, by race and ethnicity—United States, 2014–2016. *MMWR* 2018;67(41):1147–1150. doi:10.15585/mmwr.mm6741a3
4. Furukawa NW, Smith DK, Gonzalez CJ, et al. Evaluation of algorithms used for PrEP surveillance using a reference population from New York City, July 2016–June 2018. *Public Health Rep* 2020;135(2):202–210. doi:10.1177/0033354920904085
5. U.S. Census Bureau. American Community Survey 5-year data (2009–2020). https://www.census.gov/data/developers/data-sets/acs-5year.2019.html. Published March 2022. Accessed July 21, 2022.
6. U.S. Department of Housing and Urban Development (HUD). HUD USPS ZIP code crosswalk files. https://www.huduser.gov/portal/datasets/usps_crosswalk.html. Updated January 2022. Accessed July 21, 2022.
7. Grey JA, Bernstein KT, Sullivan PS, et al. Estimating the population sizes of men who have sex with men in US states and counties using data from the American Community Survey. *JMIR Public Health Surveill* 2016;2(1):e14. doi:10.2196/publichealth.5365
8. Purcell DW, Johnson CH, Lansky A, et al. Estimating the population size of men who have sex with men in the United States to obtain HIV and syphilis rates. *Open AIDS J* 2012;6:98–107. doi:10.2174/1874613601206010098
9. CDC [Smith DK, Van Handel M, Wolitski RJ, et al]. Vital Signs: Estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition—United States, 2015. *MMWR* 2015;64(46):1291–1295. doi:10.15585/mmwr.mm6446a4
10. Huang YA, Zhu W, Wiener J, Kourtis AP, Hall HI, Hoover KW. Impact of COVID-19 on HIV preexposure prophylaxis prescriptions in the United States—a time series analysis. *Clin Infect Dis* 2022:ciac038. doi:10.1093/cid/ciac038

Table 1a. Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, January 2021 through March 2022—United States *(preliminary)*

	2021 No.	2022 (January–March) No.
Gender		
Male	27,569	4,243
Female	6,345	914
Transgender woman[a]	739	78
Transgender man[a]	53	7
Additional gender identity[b]	37	6
Age at diagnosis (yr)		
13–24	6,587	911
25–34	12,793	1,927
35–44	7,371	1,147
45–54	4,286	713
≥55	3,706	550
Race/ethnicity		
American Indian/Alaska Native	223	29
Asian	713	108
Black/African American	14,231	2,020
Hispanic/Latino[c]	9,890	1,615
Native Hawaiian/other Pacific Islander	74	16
White	8,863	1,414
Multiracial	749	46
Transmission category (based on sex at birth)[d]		
Male-to-male sexual contact	23,494	3,660
Injection drug use	2,437	327
Male	1,406	184
Female	1,032	143
Male-to-male sexual contact and injection drug use	1,244	158
Heterosexual contact[e]	7,466	1,088
Male	2,165	321
Female	5,301	766
Other[f]	102	16
Male	31	4
Female	71	13
Region of residence[g]		
Northeast	4,896	583
Midwest	4,686	697
South	18,348	3,076
West	6,813	892
Total	**34,743**	**5,248**

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at diagnosis of HIV infection. Data are for cases reported to CDC through March 2022, are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

[a] "Transgender woman" includes individuals who were assigned "male" sex at birth but have ever identified as "female" gender. "Transgender man" includes individuals who were assigned "female" sex at birth but have ever identified as "male" gender.

[b] Additional gender identity examples include "bigender," "gender queer," and "two-spirit."

[c] Hispanic/Latino persons can be of any race.

[d] Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person's sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and totals. Data include transgender and additional gender identity persons.

[e] Sexual contact with a person known to have, or with a risk factor for, HIV infection.

[f] Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.

[g] Data are based on residence at time of diagnosis of HIV infection.

Table 1b. Diagnoses of HIV infection among persons aged ≥ 13 years, by selected characteristics, January 2021 through March 2022—United States and 6 dependent areas *(preliminary)*

	2021 No.	2022 (January–March) No.
Gender		
Male	27,900	4,275
Female	6,420	918
Transgender woman[a]	739	78
Transgender man[a]	53	7
Additional gender identity[b]	37	6
Age at diagnosis (yr)		
13–24	6,644	918
25–34	12,910	1,943
35–44	7,462	1,154
45–54	4,364	715
≥55	3,769	554
Race/ethnicity		
American Indian/Alaska Native	223	29
Asian	714	108
Black/African American	14,234	2,020
Hispanic/Latino[c]	10,289	1,651
Native Hawaiian/other Pacific Islander	74	16
White	8,866	1,414
Multiracial	749	46
Transmission category (based on sex at birth)[d]		
Male-to-male sexual contact	23,739	3,684
Injection drug use	2,463	328
Male	1,429	185
Female	1,034	143
Male-to-male sexual contact and injection drug use	1,247	158
Heterosexual contact[e]	7,598	1,097
Male	2,225	327
Female	5,373	770
Other[f]	102	17
Male	31	4
Female	71	13
Region of residence[g]		
Northeast	4,896	583
Midwest	4,686	697
South	18,348	3,076
West	6,813	892
U.S. dependent areas	406	36
Total	**35,149**	**5,284**

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at diagnosis of HIV infection. Data are for cases reported to CDC through March 2022, are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

[a] "Transgender woman" includes individuals who were assigned "male" sex at birth but have ever identified as "female" gender. "Transgender man" includes individuals who were assigned "female" sex at birth but have ever identified as "male" gender.

[b] Additional gender identity examples include "bigender," "gender queer," and "two-spirit."

[c] Hispanic/Latino persons can be of any race.

[d] Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person's sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and totals. Data include transgender and additional gender identity persons.

[e] Sexual contact with a person known to have, or with a risk factor for, HIV infection.

[f] Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.

[g] Data are based on residence at time of diagnosis of HIV infection.

Table 1c. Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, January 2021 through March 2022—United States and 6 dependent areas *(preliminary)*

Area of residence	2021 No.	2022 (January–March) No.
Alabama	442	69
Alaska	28	3
Arizona	804	120
Arkansas	347	64
California	4,003	429
Colorado	400	83
Connecticut	220	13
Delaware	79	15
District of Columbia	186	4
Florida	4,791	1,269
Georgia	1,957	232
Hawaii	61	7
Idaho	53	0
Illinois	1,052	136
Indiana	525	88
Iowa	124	15
Kansas	154	28
Kentucky	381	65
Louisiana	949	162
Maine	31	4
Maryland	708	17
Massachusetts	368	23
Michigan	640	116
Minnesota	297	33
Mississippi	430	47
Missouri	548	91
Montana	21	1
Nebraska	105	19
Nevada	496	92
New Hampshire	31	2
New Jersey	1,183	135
New Mexico	148	12
New York	2,089	256
North Carolina	1,387	299
North Dakota	30	0
Ohio	926	127
Oklahoma	320	40
Oregon	198	51
Pennsylvania	903	150
Rhode Island	63	0
South Carolina	658	21
South Dakota	30	4
Tennessee	823	148
Texas	3,943	443
Utah	127	3
Vermont	8	0
Virginia	800	150
Washington	467	87
West Virginia	147	31
Wisconsin	255	40
Wyoming	7	4
Subtotal	34,743	5,248
U.S. dependent areas		
American Samoa	0	0
Guam	1	0
Northern Mariana Islands	0	0
Puerto Rico	400	36
Republic of Palau	0	0
U.S. Virgin Islands	5	0
Subtotal	406	36
Total	**35,149**	**5,284**

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at diagnosis of HIV infection. Data are for cases reported to CDC through March 2022, are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

Table 1d. Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, January 2021 through March 2022—Ending the HIV Epidemic Phase I jurisdictions *(preliminary)*

Area of residence	2021 No.	2022 (January–March) No.
Arizona		
Maricopa County	530	85
California		
Alameda County	186	31
Los Angeles County	1,368	125
Orange County	264	43
Riverside County	234	37
Sacramento County	121	7
San Bernardino County	290	21
San Diego County	240	0
San Francisco County	188	31
District of Columbia	186	4
Florida		
Broward County	677	177
Duval County	298	67
Hillsborough County	332	89
Miami-Dade County	1,248	369
Orange County	476	130
Palm Beach County	313	32
Pinellas County	136	48
Georgia		
Cobb County	123	11
DeKalb County	283	28
Fulton County	470	66
Gwinnett County	128	13
Illinois		
Cook County	750	103
Indiana		
Marion County	216	32
Louisiana		
East Baton Rouge Parish	152	21
Orleans Parish	150	30
Maryland		
Baltimore City	136	2
Montgomery County	94	1
Prince George's County	209	8
Massachusetts		
Suffolk County	115	8
Michigan		
Wayne County	253	48
Nevada		
Clark County	443	80
New Jersey		
Essex County	276	36
Hudson County	169	27

Table 1d. Diagnoses of HIV infection among persons aged ≥ 13 years, by area of residence, January 2021 through March 2022—Ending the HIV Epidemic Phase I jurisdictions *(preliminary) (cont)*

Area of residence	2021 No.	2022 (January–March) No.
New York		
Bronx County	401	42
Kings County	434	55
New York County	329	41
Queens County	336	34
North Carolina		
Mecklenburg County	277	57
Ohio		
Cuyahoga County	172	26
Franklin County	187	21
Hamilton County	127	17
Pennsylvania		
Philadelphia County	332	65
Puerto Rico		
San Juan Municipio	100	8
Tennessee		
Shelby County	296	61
Texas		
Bexar County	329	30
Dallas County	758	99
Harris County	1,114	144
Tarrant County	303	31
Travis County	224	30
Washington		
King County	226	63

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at diagnosis of HIV infection. Data are for cases reported to CDC through March 2022, are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

Table 2a. Linkage to HIV medical care within 1 month of HIV diagnosis during 2021 among persons aged ≥13 years, by selected characteristics—45 states and the District of Columbia *(preliminary)*

	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
Gender					
Male	25,614	21,131	82.5	4,483	17.5
Female	5,813	4,769	82.0	1,044	18.0
Transgender woman[a]	703	594	84.5	109	15.5
Transgender man[a]	52	46	88.5	6	11.5
Additional gender identity[b]	33	28	84.8	5	15.2
Age at diagnosis (yr)					
13–24	6,167	4,959	80.4	1,208	19.6
25–34	11,890	9,786	82.3	2,104	17.7
35–44	6,799	5,632	82.8	1,167	17.2
45–54	3,943	3,315	84.1	628	15.9
≥55	3,416	2,876	84.2	540	15.8
Race/ethnicity					
American Indian/Alaska Native	220	181	82.3	39	17.7
Asian	667	593	88.9	74	11.1
Black/African American	13,196	10,556	80.0	2,640	20.0
Hispanic/Latino[c]	9,229	7,880	85.4	1,349	14.6
Native Hawaiian/other Pacific Islander	71	56	78.9	15	21.1
White	8,151	6,733	82.6	1,418	17.4
Multiracial	681	569	83.6	112	16.4
Transmission category (based on sex at birth)[d]					
Male-to-male sexual contact	21,992	18,268	83.1	3,724	16.9
Injection drug use	2,163	1,668	77.1	495	22.9
Male	1,236	941	76.1	295	23.9
Female	927	727	78.5	200	21.5
Male-to-male sexual contact and injection drug use	1,150	920	80.0	230	20.0
Heterosexual contact[e]	6,817	5,636	82.7	1,181	17.3
Male	1,941	1,600	82.4	341	17.6
Female	4,877	4,036	82.8	840	17.2
Total[f]	**32,215**	**26,568**	**82.5**	**5,647**	**17.5**

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at diagnosis of HIV infection. Data are for cases reported to CDC through March 2022, are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kentucky, Pennsylvania (excluding Philadelphia), and Vermont.

[a] "Transgender woman" includes individuals who were assigned "male" sex at birth but have ever identified as "female" gender. "Transgender man" includes individuals who were assigned "female" sex at birth but have ever identified as "male" gender.

[b] Additional gender identity examples include "bigender," "gender queer," and "two-spirit."

[c] Hispanic/Latino persons can be of any race.

[d] Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person's sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and totals. Data include transgender and additional gender identity persons.

[e] Sexual contact with a person known to have, or with a risk factor for, HIV infection.

[f] Includes persons whose infection was attributed to hemophilia, blood transfusion, or perinatal exposure or whose risk factor was not reported or not identified; data not displayed because the numbers were too small to be meaningful.

Table 2b. Linkage to HIV medical care within 1 month of HIV diagnosis during 2021 among persons aged ≥13 years, by area of residence—45 states and the District of Columbia *(preliminary)*

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
Alabama	442	320	72.4	122	27.6
Alaska	28	26	92.9	2	7.1
Arizona	804	684	85.1	120	14.9
Arkansas	347	269	77.5	78	22.5
California	4,003	3,359	83.9	644	16.1
Colorado	400	338	84.5	62	15.5
Connecticut	220	194	88.2	26	11.8
Delaware	79	67	84.8	12	15.2
District of Columbia	186	154	82.8	32	17.2
Florida	4,791	4,051	84.6	740	15.4
Georgia	1,957	1,652	84.4	305	15.6
Hawaii	61	54	88.5	7	11.5
Illinois	1,052	899	85.5	153	14.5
Indiana	525	405	77.1	120	22.9
Iowa	124	106	85.5	18	14.5
Kansas	154	140	90.9	14	9.1
Louisiana	949	762	80.3	187	19.7
Maine	31	27	87.1	4	12.9
Maryland	708	637	90.0	71	10.0
Massachusetts	368	342	92.9	26	7.1
Michigan	640	557	87.0	83	13.0
Minnesota	297	235	79.1	62	20.9
Mississippi	430	305	70.9	125	29.1
Missouri	548	428	78.1	120	21.9
Montana	21	20	95.2	1	4.8
Nebraska	105	89	84.8	16	15.2
Nevada	496	434	87.5	62	12.5
New Hampshire	31	31	100	0	0.0
New Mexico	148	128	86.5	20	13.5
New York	2,089	1,803	86.3	286	13.7
North Carolina	1,387	1,115	80.4	272	19.6
North Dakota	30	26	86.7	4	13.3
Ohio	926	777	83.9	149	16.1
Oklahoma	320	235	73.4	85	26.6
Oregon	198	156	78.8	42	21.2
Rhode Island	63	38	60.3	25	39.7
South Carolina	658	568	86.3	90	13.7
South Dakota	30	26	86.7	4	13.3
Tennessee	823	577	70.1	246	29.9
Texas	3,943	3,032	76.9	911	23.1
Utah	127	110	86.6	17	13.4
Virginia	800	635	79.4	165	20.6
Washington	467	414	88.7	53	11.3
West Virginia	147	110	74.8	37	25.2
Wisconsin	255	227	89.0	28	11.0
Wyoming	7	6	85.7	1	14.3
Total	**32,215**	**26,568**	**82.5**	**5,647**	**17.5**

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at diagnosis of HIV infection. Data are for cases reported to CDC through March 2022, are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kentucky, Pennsylvania, Puerto Rico, and Vermont.

Table 2c. Linkage to HIV medical care within 1 month of HIV diagnosis during 2021 among persons aged ≥13 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions *(preliminary)*

Area of residence	Total diagnoses No.	≥1 CD4 or VL tests No.	≥1 CD4 or VL tests %	No CD4 or VL test No.	No CD4 or VL test %
Arizona					
Maricopa County	530	463	87.4	67	12.6
California					
Alameda County	186	165	88.7	21	11.3
Los Angeles County	1,368	1,138	83.2	230	16.8
Orange County	264	229	86.7	35	13.3
Riverside County	234	181	77.4	53	22.6
Sacramento County	121	109	90.1	12	9.9
San Bernardino County	290	222	76.6	68	23.4
San Diego County	240	200	83.3	40	16.7
San Francisco County	188	179	95.2	9	4.8
District of Columbia	186	154	82.8	32	17.2
Florida					
Broward County	677	570	84.2	107	15.8
Duval County	298	235	78.9	63	21.1
Hillsborough County	332	271	81.6	61	18.4
Miami-Dade County	1,248	1,076	86.2	172	13.8
Orange County	476	399	83.8	77	16.2
Palm Beach County	313	263	84.0	50	16.0
Pinellas County	136	111	81.6	25	18.4
Georgia					
Cobb County	123	107	87.0	16	13.0
DeKalb County	283	245	86.6	38	13.4
Fulton County	470	399	84.9	71	15.1
Gwinnett County	128	116	90.6	12	9.4
Illinois					
Cook County	750	648	86.4	102	13.6
Indiana					
Marion County	216	173	80.1	43	19.9
Louisiana					
East Baton Rouge Parish	152	119	78.3	33	21.7
Orleans Parish	150	136	90.7	14	9.3
Maryland					
Baltimore City	136	124	91.2	12	8.8
Montgomery County	94	87	92.6	7	7.4
Prince George's County	209	179	85.6	30	14.4
Massachusetts					
Suffolk County	115	111	96.5	4	3.5
Michigan					
Wayne County	253	215	85.0	38	15.0
Nevada					
Clark County	443	385	86.9	58	13.1
New York					
Bronx County	401	348	86.8	53	13.2
Kings County	434	374	86.2	60	13.8
New York County	329	272	82.7	57	17.3
Queens County	336	291	86.6	45	13.4

Table 2c. Linkage to HIV medical care within 1 month of HIV diagnosis during 2021 among persons aged ≥13 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions *(preliminary) (cont)*

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
North Carolina					
Mecklenburg County	277	226	81.6	51	18.4
Ohio					
Cuyahoga County	172	155	90.1	17	9.9
Franklin County	187	163	87.2	24	12.8
Hamilton County	127	113	89.0	14	11.0
Pennsylvania					
Philadelphia County	332	278	83.7	54	16.3
Tennessee					
Shelby County	296	177	59.8	119	40.2
Texas					
Bexar County	329	255	77.5	74	22.5
Dallas County	758	580	76.5	178	23.5
Harris County	1,114	845	75.9	269	24.1
Tarrant County	303	218	71.9	85	28.1
Travis County	224	177	79.0	47	21.0
Washington					
King County	226	202	89.4	24	10.6

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at diagnosis of HIV infection. Data are for cases reported to CDC through March 2022, are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kentucky, Pennsylvania (excluding Philadelphia), Puerto Rico, and Vermont.

Table 3a. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through December 2021 among persons aged ≥16 years, by selected characteristics—United States

	Persons prescribed PrEP[a] No.	Persons with PrEP indications[b] No.	PrEP coverage[c] %
	2019		
Sex at birth			
Male	254,553	989,200	25.7
Female	21,088	227,010	9.3
Age (yr)			
16–24	37,649	246,290	15.3
25–34	111,869	434,680	25.7
35–44	64,235	238,470	26.9
45–54	37,602	173,420	21.7
≥55	24,342	123,350	19.7
Race/ethnicity[d]			
Black/African American	37,496	468,540	8.0
Hispanic/Latino[e]	43,794	312,820	14.0
Other	11,715	131,180	8.9
White	182,779	300,650	60.8
Total	**275,784**	**1,216,210**	**22.7**
	2020 (COVID-19 pandemic)		
Sex at birth			
Male	277,901	989,200	28.1
Female	23,645	227,010	10.4
Age (yr)			
16–24	37,772	246,290	15.3
25–34	120,535	434,680	27.7
35–44	72,087	238,470	30.2
45–54	40,673	173,420	23.5
≥55	30,445	123,350	24.7
Race/ethnicity[d]			
Black/African American	42,740	468,540	9.1
Hispanic/Latino[e]	49,381	312,820	15.8
Other	12,363	131,180	9.4
White	197,129	300,650	65.6
Total	**301,613**	**1,216,210**	**24.8**
	2021		
Sex at birth			
Male	339,337	989,200	34.3
Female	28,160	227,010	12.4
Age (yr)			
16–24	48,701	246,290	19.8
25–34	146,291	434,680	33.7
35–44	88,943	238,470	37.3
45–54	46,552	173,420	26.8
≥55	37,120	123,350	30.1
Race/ethnicity[d]			
Black/African American	51,852	468,540	11.1
Hispanic/Latino[e]	61,399	312,820	19.6
Other	15,124	131,180	11.5
White	239,413	300,650	79.6
Total	**367,787**	**1,216,210**	**30.2**

Abbreviations: PrEP, preexposure prophylaxis; FDA, Food and Drug Administration [footnotes only].

Note. Data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

[a] Estimated by using data from IQVIA pharmacy database reported through December 2021 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported; thus, values may not sum to column total.

[b] Estimated by using 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator.

[c] PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

[d] Race/ethnicity data were only available for <40% of persons prescribed PrEP in each year. Number prescribed PrEP and PrEP coverage for race/ethnicity reported in the table were adjusted applying the distribution of records with known race/ethnicity to records with missing race/ethnicity.

[e] Hispanic/Latino persons can be of any race.

Table 3b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through December 2021 among persons aged ≥16 years, by area of residence—United States and Puerto Rico

Area of residence	Persons prescribed PrEP[a] No.	Persons with PrEP indications[b] No.	PrEP coverage[c] %
		2019	
Alabama	1,842	11,020	16.7
Alaska	230	1,780	12.9
Arizona	4,587	25,780	17.8
Arkansas	731	5,130	14.2
California	41,711	165,030	25.3
Colorado	4,403	25,120	17.5
Connecticut	2,677	9,560	28.0
Delaware	470	4,400	10.7
District of Columbia	5,880	12,950	45.4
Florida	21,794	125,330	17.4
Georgia	8,663	39,030	22.2
Hawaii	814	4,360	18.7
Idaho	475	4,790	9.9
Illinois	16,651	55,860	29.8
Indiana	2,987	22,170	13.5
Iowa	1,428	4,760	30.0
Kansas	903	5,060	17.8
Kentucky	1,611	12,990	12.4
Louisiana	3,951	15,920	24.8
Maine	643	3,950	16.3
Maryland	4,951	27,300	18.1
Massachusetts	9,311	24,900	37.4
Michigan	4,361	29,570	14.7
Minnesota	4,200	21,720	19.3
Mississippi	947	4,530	20.9
Missouri	3,485	18,370	19.0
Montana	267	2,290	11.7
Nebraska	622	2,180	28.5
Nevada	2,187	11,390	19.2
New Hampshire	617	3,020	20.4
New Jersey	5,714	25,280	22.6
New Mexico	1,077	6,800	15.8
New York	35,352	72,640	48.7
North Carolina	5,399	32,490	16.6
North Dakota	191	1,520	12.6
Ohio	6,129	40,320	15.2
Oklahoma	1,156	11,030	10.5
Oregon	3,391	19,750	17.2
Pennsylvania	10,144	36,490	27.8
Puerto Rico	331	9,700	3.4
Rhode Island	1,080	3,880	27.8
South Carolina	1,728	10,390	16.6
South Dakota	151	910	16.6
Tennessee	3,906	22,460	17.4
Texas	23,143	123,790	18.7
Utah	2,036	6,840	29.8
Vermont	337	1,060	31.8
Virginia	4,416	31,430	14.1
Washington	9,874	40,050	24.7
West Virginia	569	5,250	10.8
Wisconsin	2,477	12,980	19.1
Wyoming	96	890	10.8

Table 3b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through December 2021 among persons aged ≥16 years, by area of residence—United States and Puerto Rico *(cont)*

Area of residence	Persons prescribed PrEP[a] No.	Persons with PrEP indications[b] No.	PrEP coverage[c] %
	2020 (COVID-19 pandemic)		
Alabama	1,919	11,020	17.4
Alaska	245	1,780	13.8
Arizona	5,075	25,780	19.7
Arkansas	869	5,130	16.9
California	42,394	165,030	25.7
Colorado	4,793	25,120	19.1
Connecticut	2,480	9,560	25.9
Delaware	467	4,400	10.6
District of Columbia	5,973	12,950	46.1
Florida	34,620	125,330	27.6
Georgia	9,788	39,030	25.1
Hawaii	903	4,360	20.7
Idaho	663	4,790	13.8
Illinois	15,977	55,860	28.6
Indiana	3,214	22,170	14.5
Iowa	1,564	4,760	32.9
Kansas	949	5,060	18.8
Kentucky	1,669	12,990	12.8
Louisiana	3,598	15,920	22.6
Maine	663	3,950	16.8
Maryland	4,819	27,300	17.7
Massachusetts	9,387	24,900	37.7
Michigan	4,682	29,570	15.8
Minnesota	4,219	21,720	19.4
Mississippi	1,097	4,530	24.2
Missouri	3,576	18,370	19.5
Montana	293	2,290	12.8
Nebraska	726	2,180	33.3
Nevada	2,509	11,390	22.0
New Hampshire	648	3,020	21.5
New Jersey	5,940	25,280	23.5
New Mexico	1,237	6,800	18.2
New York	34,204	72,640	47.1
North Carolina	6,166	32,490	19.0
North Dakota	187	1,520	12.3
Ohio	6,845	40,320	17.0
Oklahoma	1,527	11,030	13.8
Oregon	3,822	19,750	19.4
Pennsylvania	10,599	36,490	29.0
Puerto Rico	368	9,700	3.8
Rhode Island	1,150	3,880	29.6
South Carolina	2,116	10,390	20.4
South Dakota	146	910	16.0
Tennessee	5,172	22,460	23.0
Texas	27,557	123,790	22.3
Utah	2,381	6,840	34.8
Vermont	320	1,060	30.2
Virginia	5,134	31,430	16.3
Washington	10,043	40,050	25.1
West Virginia	523	5,250	10.0
Wisconsin	2,535	12,980	19.5
Wyoming	100	890	11.2

Table 3b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through December 2021 among persons aged ≥16 years, by area of residence—United States and Puerto Rico *(cont)*

Area of residence	Persons prescribed PrEP[a] No.	Persons with PrEP indications[b] No.	PrEP coverage[c] %
	2021		
Alabama	2,790	11,020	25.3
Alaska	305	1,780	17.1
Arizona	6,598	25,780	25.6
Arkansas	1,290	5,130	25.1
California	50,476	165,030	30.6
Colorado	6,204	25,120	24.7
Connecticut	3,068	9,560	32.1
Delaware	634	4,400	14.4
District of Columbia	6,779	12,950	52.3
Florida	42,788	125,330	34.1
Georgia	12,238	39,030	31.4
Hawaii	1,139	4,360	26.1
Idaho	871	4,790	18.2
Illinois	18,428	55,860	33.0
Indiana	4,290	22,170	19.4
Iowa	1,964	4,760	41.3
Kansas	1,280	5,060	25.3
Kentucky	2,248	12,990	17.3
Louisiana	4,193	15,920	26.3
Maine	906	3,950	22.9
Maryland	5,832	27,300	21.4
Massachusetts	10,205	24,900	41.0
Michigan	5,948	29,570	20.1
Minnesota	5,284	21,720	24.3
Mississippi	1,605	4,530	35.4
Missouri	4,182	18,370	22.8
Montana	392	2,290	17.1
Nebraska	1,016	2,180	46.6
Nevada	4,907	11,390	43.1
New Hampshire	800	3,020	26.5
New Jersey	7,313	25,280	28.9
New Mexico	1,596	6,800	23.5
New York	39,230	72,640	54.0
North Carolina	7,978	32,490	24.6
North Dakota	245	1,520	16.1
Ohio	8,535	40,320	21.2
Oklahoma	2,340	11,030	21.2
Oregon	4,693	19,750	23.8
Pennsylvania	13,131	36,490	36.0
Puerto Rico	610	9,700	6.3
Rhode Island	1,518	3,880	39.1
South Carolina	2,964	10,390	28.5
South Dakota	219	910	24.1
Tennessee	7,266	22,460	32.4
Texas	34,859	123,790	28.2
Utah	3,296	6,840	48.2
Vermont	483	1,060	45.6
Virginia	6,305	31,430	20.1
Washington	11,401	40,050	28.5
West Virginia	714	5,250	13.6
Wisconsin	2,834	12,980	21.8
Wyoming	142	890	16.0

Abbreviations: PrEP, preexposure prophylaxis; FDA, Food and Drug Administration [footnotes only].

Note. Data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

[a] Estimated by using data from IQVIA pharmacy database reported through December 2021 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported; thus, values may not sum to column total.

[b] Estimated by using 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator.

[c] PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through December 2021 among persons aged ≥16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions

Area of residence	Persons prescribed PrEP[a] No.	Persons with PrEP indications[b] No.	PrEP coverage[c] %
	2019		
Arizona			
Maricopa County	3,548	22,720	15.6
California			
Alameda County	2,186	8,930	24.5
Los Angeles County	13,740	67,450	20.4
Orange County	2,036	10,510	19.4
Riverside County	1,784	11,080	16.1
Sacramento County	957	5,920	16.2
San Bernardino County	756	11,890	6.4
San Diego County	3,720	14,500	25.7
San Francisco County	8,826	10,840	81.4
District of Columbia	5,880	12,950	45.4
Florida			
Broward County	3,810	20,470	18.6
Duval County	507	8,970	5.7
Hillsborough County	1,381	12,910	10.7
Miami-Dade County	6,509	21,760	29.9
Orange County	2,780	15,310	18.2
Palm Beach County	880	9,170	9.6
Pinellas County	1,129	9,530	11.8
Georgia			
Cobb County	560	3,070	18.2
DeKalb County	1,566	6,290	24.9
Fulton County	3,310	13,120	25.2
Gwinnett County	679	3,240	21.0
Illinois			
Cook County	13,610	39,060	34.8
Indiana			
Marion County	1,145	9,150	12.5
Louisiana			
East Baton Rouge Parish	494	1,810	27.3
Orleans Parish	1,524	4,590	33.2
Maryland			
Baltimore City	903	5,770	15.6
Montgomery County	813	4,040	20.1
Prince George's County	901	6,330	14.2
Massachusetts			
Suffolk County	2,769	6,520	42.5
Michigan			
Wayne County	1,205	9,270	13.0
Nevada			
Clark County	1,871	11,670	16.0
New Jersey			
Essex County	680	4,090	16.6
Hudson County	1,054	4,650	22.7

Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through December 2021 among persons aged ≥16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions *(cont)*

Area of residence	Persons prescribed PrEP[a] No.	Persons with PrEP indications[b] No.	PrEP coverage[c] %
	2019 *(cont)*		
New York			
Bronx County	2,218	5,570	39.8
Kings County	7,554	15,650	48.3
New York County	14,141	15,540	91.0
Queens County	3,876	9,230	42.0
North Carolina			
Mecklenburg County	1,348	8,450	16.0
Ohio			
Cuyahoga County	960	7,520	12.8
Franklin County	2,042	11,620	17.6
Hamilton County	565	7,720	7.3
Pennsylvania			
Philadelphia County	3,661	9,840	37.2
Puerto Rico			
San Juan Municipio[d]	N/A	2,190	N/A
Tennessee			
Shelby County	633	6,450	9.8
Texas			
Bexar County	1,519	11,920	12.7
Dallas County	4,110	28,670	14.3
Harris County	4,943	40,670	12.2
Tarrant County	1,459	11,340	12.9
Travis County	4,556	11,590	39.3
Washington			
King County	6,903	17,890	38.6

Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through December 2021 among persons aged ≥16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions *(cont)*

Area of residence	Persons prescribed PrEP[a] No.	Persons with PrEP indications[b] No.	PrEP coverage[c] %
	2020 (COVID-19 pandemic)		
Arizona			
Maricopa County	3,899	22,720	17.2
California			
Alameda County	2,042	8,930	22.9
Los Angeles County	14,804	67,450	21.9
Orange County	2,206	10,510	21.0
Riverside County	1,921	11,080	17.3
Sacramento County	977	5,920	16.5
San Bernardino County	818	11,890	6.9
San Diego County	3,779	14,500	26.1
San Francisco County	8,100	10,840	74.7
District of Columbia	5,973	12,950	46.1
Florida			
Broward County	6,731	20,470	32.9
Duval County	742	8,970	8.3
Hillsborough County	1,532	12,910	11.9
Miami-Dade County	10,273	21,760	47.2
Orange County	3,884	15,310	25.4
Palm Beach County	3,017	9,170	32.9
Pinellas County	1,217	9,530	12.8
Georgia			
Cobb County	646	3,070	21.0
DeKalb County	1,722	6,290	27.4
Fulton County	3,598	13,120	27.4
Gwinnett County	788	3,240	24.3
Illinois			
Cook County	12,882	39,060	33.0
Indiana			
Marion County	1,207	9,150	13.2
Louisiana			
East Baton Rouge Parish	531	1,810	29.3
Orleans Parish	1,341	4,590	29.2
Maryland			
Baltimore City	911	5,770	15.8
Montgomery County	828	4,040	20.5
Prince George's County	857	6,330	13.5
Massachusetts			
Suffolk County	2,807	6,520	43.1
Michigan			
Wayne County	1,236	9,270	13.3
Nevada			
Clark County	2,110	11,670	18.1
New Jersey			
Essex County	708	4,090	17.3
Hudson County	1,056	4,650	22.7

Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through December 2021 among persons aged ≥16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions *(cont)*

Area of residence	Persons prescribed PrEP[a] No.	Persons with PrEP indications[b] No.	PrEP coverage[c] %
	2020 (COVID-19 pandemic) *(cont)*		
New York			
Bronx County	2,047	5,570	36.8
Kings County	7,418	15,650	47.4
New York County	13,747	15,540	88.5
Queens County	3,811	9,230	41.3
North Carolina			
Mecklenburg County	1,578	8,450	18.7
Ohio			
Cuyahoga County	970	7,520	12.9
Franklin County	2,315	11,620	19.9
Hamilton County	632	7,720	8.2
Pennsylvania			
Philadelphia County	3,494	9,840	35.5
Puerto Rico			
San Juan Municipio[d]	N/A	2,190	N/A
Tennessee			
Shelby County	809	6,450	12.5
Texas			
Bexar County	1,777	11,920	14.9
Dallas County	5,186	28,670	18.1
Harris County	5,994	40,670	14.7
Tarrant County	1,654	11,340	14.6
Travis County	5,070	11,590	43.7
Washington			
King County	6,975	17,890	39.0

Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through December 2021 among persons aged ≥16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions *(cont)*

Area of residence	Persons prescribed PrEP[a] No.	Persons with PrEP indications[b] No.	PrEP coverage[c] %
	2021		
Arizona			
Maricopa County	5,039	22,720	22.2
California			
Alameda County	2,231	8,930	25.0
Los Angeles County	18,592	67,450	27.6
Orange County	2,849	10,510	27.1
Riverside County	2,522	11,080	22.8
Sacramento County	1,098	5,920	18.5
San Bernardino County	1,198	11,890	10.1
San Diego County	4,422	14,500	30.5
San Francisco County	8,147	10,840	75.2
District of Columbia	6,779	12,950	52.3
Florida			
Broward County	8,277	20,470	40.4
Duval County	902	8,970	10.1
Hillsborough County	2,016	12,910	15.6
Miami-Dade County	11,543	21,760	53.0
Orange County	4,711	15,310	30.8
Palm Beach County	2,773	9,170	30.2
Pinellas County	1,657	9,530	17.4
Georgia			
Cobb County	804	3,070	26.2
DeKalb County	2,069	6,290	32.9
Fulton County	4,281	13,120	32.6
Gwinnett County	993	3,240	30.6
Illinois			
Cook County	14,738	39,060	37.7
Indiana			
Marion County	1,593	9,150	17.4
Louisiana			
East Baton Rouge Parish	598	1,810	33.0
Orleans Parish	1,527	4,590	33.3
Maryland			
Baltimore City	1,153	5,770	20.0
Montgomery County	1,005	4,040	24.9
Prince George's County	991	6,330	15.7
Massachusetts			
Suffolk County	2,814	6,520	43.2
Michigan			
Wayne County	1,562	9,270	16.9
Nevada			
Clark County	4,316	11,670	37.0
New Jersey			
Essex County	842	4,090	20.6
Hudson County	1,287	4,650	27.7

Table 3c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2019 through December 2021 among persons aged ≥16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions *(cont)*

Area of residence	Persons prescribed PrEP[a] No.	Persons with PrEP indications[b] No.	PrEP coverage[c] %
	2021 *(cont)*		
New York			
Bronx County	2,106	5,570	37.8
Kings County	8,860	15,650	56.6
New York County	15,772	15,540	101.5
Queens County	4,297	9,230	46.6
North Carolina			
Mecklenburg County	1,958	8,450	23.2
Ohio			
Cuyahoga County	1,273	7,520	16.9
Franklin County	2,754	11,620	23.7
Hamilton County	815	7,720	10.6
Pennsylvania			
Philadelphia County	4,052	9,840	41.2
Puerto Rico			
San Juan Municipio	63	2,190	2.9
Tennessee			
Shelby County	941	6,450	14.6
Texas			
Bexar County	2,358	11,920	19.8
Dallas County	6,592	28,670	23.0
Harris County	7,518	40,670	18.5
Tarrant County	2,135	11,340	18.8
Travis County	5,815	11,590	50.2
Washington			
King County	7,666	17,890	42.9

Abbreviations: PrEP, preexposure prophylaxis; n/a, not available; FDA, Food and Drug Administration [footnotes only].

Note. Data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

[a] Estimated by using data from IQVIA pharmacy database reported through December 2021 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported; thus, values may not sum to column total.

[b] Estimated by using 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator.

[c] PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

[d] Data value <40 was not reported due to unreliability.

Table 4. Ending the HIV Epidemic Phase I jurisdictions

Counties	Territories	States
Arizona	**Puerto Rico**[a]	Alabama
Maricopa County	San Juan Municipio[a]	Arkansas
California		Kentucky[a]
Alameda County		Mississippi
Los Angeles County		Missouri
Orange County		Oklahoma
Riverside County		South Carolina
Sacramento County		
San Bernardino County		
San Diego County		
San Francisco County		
District of Columbia		
Florida		
Broward County		
Duval County		
Hillsborough County		
Miami-Dade County		
Orange County		
Palm Beach County		
Pinellas County		
Georgia		
Cobb County		
DeKalb County		
Fulton County		
Gwinnett County		
Illinois		
Cook County		
Indiana		
Marion County		
Louisiana		
East Baton Rouge Parish		
Orleans Parish		
Maryland		
Baltimore City		
Montgomery County		
Prince George's County		
Massachusetts		
Suffolk County		
Michigan		
Wayne County		
Nevada		
Clark County		
New Jersey[b]		
Essex County[b]		
Hudson County[b]		
New York		
Bronx County		
Kings County		
New York County		
Queens County		

Table 4. Ending the HIV Epidemic Phase I jurisdictions *(cont)*

Counties	Territories	States
North Carolina		
Mecklenburg County		
Ohio		
Cuyahoga County		
Franklin County		
Hamilton County		
Pennsylvania[a]		
Philadelphia County		
Tennessee		
Shelby County		
Texas		
Bexar County		
Dallas County		
Harris County		
Tarrant County		
Travis County		
Washington		
King County		

Abbreviations: CDC, the Centers for Disease Control and Prevention [footnotes only]; PrEP, preexposure prophylaxis [footnotes only]; CD4, CD4+ T-lymphocyte count (cells/μL) or percentage [footnotes only].

Note. For more information on the Ending the HIV Epidemic in the U.S. initiative, see https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview.

[a] Linkage to care data are not provided for states and associated jurisdictions that have incomplete reporting of laboratory data to CDC: Kentucky, Pennsylvania (excluding Philadelphia), Puerto Rico, and Vermont.

[b] Linkage to care data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral load laboratory results: New Jersey.